John Newman, an analyst from Canaccord Genuity, maintained the Buy rating on BioNTech SE (BNTX – Research Report). The associated price target remains the same with $171.00.
John Newman has given his Buy rating due to a combination of factors that highlight BioNTech SE’s promising future prospects. One of the main reasons is the company’s robust oncology pipeline, which is expected to drive significant long-term value. The BNT327 trial in non-small cell lung cancer (NSCLC) is particularly noteworthy, as its design differentiates it from other trials, potentially offering a competitive advantage. Additionally, the anticipated BLA submission for BNT323 targeting HER2+ endometrial cancer by the end of 2025 is expected to expand revenue opportunities beyond COVID-19 vaccines.
Furthermore, the expected data from the BNT122 trial in colorectal cancer by late 2025 or early 2026 is seen as a major catalyst for the company, with positive outcomes anticipated. Despite potential changes in COVID-19 vaccination recommendations, the impact on BioNTech is considered manageable, especially given the focus on immunocompromised and older patients. Overall, these factors contribute to a positive outlook for BioNTech, justifying the Buy rating and a price target of $171.
In another report released yesterday, Citi also maintained a Buy rating on the stock with a $140.00 price target.
BNTX’s price has also changed slightly for the past six months – from $110.970 to $101.100, which is a -8.89% drop .